@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix chebi: . @prefix go: . @prefix Protein: . @prefix sfam: . @prefix geneProductOf: . @prefix hasAgent: . @prefix obo: . @prefix occursIn: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 hasAgent: sub:_2; a go:0016301 . sub:_2 geneProductOf: sfam:MAPK%20Erk1%2F2%20Family; a Protein: . sub:_3 occursIn: obo:CL_0000115, obo:UBERON_0004535, species:10116; rdf:object sub:_1; rdf:predicate belv:increases; rdf:subject chebi:7242; a rdf:Statement . sub:assertion rdfs:label "a(CHEBI:ceramide) -> kin(p(SFAM:\"MAPK Erk1/2 Family\"))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_5; pav:version "20131211" . sub:_4 prov:value "Treatment with ceramide induced marked activation of ERK1/2 within 10 min, which peaked at 20 min, as detected by Western blotting (Figure 7 b). However, the decrease in TER induced by ceramide treatment was not attenuated by pretreatment with p38-, JNK-, or ERK1/2-inhibitors (Figure 7 c)."; prov:wasQuotedFrom pubmed:21873444 . sub:_5 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:21873444; prov:wasDerivedFrom beldoc:, sub:_4 . } sub:pubinfo { this: dct:created "2014-07-03T14:33:41.637+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }